

27 Nov 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer's meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck's Frazier cautions against profit maximization.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 November 2022, including: a preview of the CTAD Alzheimer's meeting; US myeloma drug withdrawal puts pressure on [GSK plc](#); [uniQure N.V./CSL Limited](#)'s gene therapy sets record US price; new leadership at [Teva Pharmaceutical Industries Ltd.](#); and [Merck & Co., Inc.](#)'s Frazier cautions against profit maximization.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab's Failure](#)" - Scrip, 22 Nov, 2022.)

(Also see "[Blenrep US Withdrawal Is A Big Blow To GSK's Blockbuster Hopes](#)" - Scrip, 22 Nov, 2022.)

(Also see "[UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price](#)" - Scrip, 23 Nov, 2022.)

(Also see "[Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization](#)" - Scrip, 21 Nov, 2022.)

(Also see "[Departing Words: Merck's Ken Frazier Cautions Against Profit Maximization](#)" - Scrip, 21 Nov, 2022.)

[Click here to explore this interactive content online](#) ✨